CatalystWireBeta

Full Year 2026 Trading Update

In brief · summary, not quotable

Kromek Group PLC expects to report full-year revenues and profit before tax in line with market expectations, with consensus estimates of £27.2 million and £2.15 million respectively for the period ended 30 April 2026. The company saw increased revenue in its CBRN Detection division and good underlying growth in Advanced Imaging, excluding the Siemens Healthineers enablement agreement. Both divisions secured new orders totaling £8.8 million in the second half of the year, with a significant portion delivered before year-end, demonstrating resilience and technological relevance in mission-critical applications.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your KMK notes

Kromek (AIM: KMK), a global detection company focused on the advanced imaging and CBRN detection markets, provides the following trading update for the 12-month period ended 30 April 2026 ("FY26").

The Group expects to report revenues and PBT for FY26 in line with market expectations*. Results reflect increased revenue in the CBRN Detection division and good underlying growth in the Advanced Imaging division, excluding the exceptional contribution from the Group's enablement agreement with Siemens Healthineers, as previously announced.

The Group continued to see demand across its end markets during the year, with both divisions making further operational and commercial progress. In the second half of the year, alongside the execution of previously secured contracts, the CBRN Detection and Advanced Imaging divisions won new orders totaling £8.8m, a significant proportion of which was delivered before year end. The Board believes that the full year performance demonstrates the resilience of the Group's business model, the strength of its customer relationships and the growing relevance of its technology in mission-critical applications.

In the Advanced Imaging division, excluding contribution from the Siemens Healthineers agreements, the Group continued to deliver on its long-term contracts, achieving good underlying revenue growth. While the division faced supply chain disruptions due to the various global trade and geopolitical tensions, these challenges primarily affected the timing of order fulfilments. Nonetheless, the impact of these disruptions was significantly mitigated by securing and delivering a major new order from an existing customer in the second half of the year. The performance of this division reaffirms the management team's belief in the critical role of Kromek's products and solutions in its customers' transition towards next generation photon counting CT and SPECT scanners.

In the CBRN Detection division, the Group also expects to report year-on-year revenue growth. Growth in the period was supported by continued global demand for the Group's products and was delivered despite delays in certain governmental contracts progressing to the procurement stage.

The Group ended the year with continued momentum and remains focused on executing against its strategic priorities and continued growth across both divisions. The Board looks forward to reporting on the Group's progress at the time of its full year results announcement, which is expected to be in September 2026.

* The Company understands FY26 consensus estimates to be revenues of £27.2 million and PBT of £2.15 million.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note